{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 39,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/23",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.25,
        "x": 0.68,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Reduction in ROS1 G2032R Allele: Complete clearance in 7/7 patients",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f1e8b84-b871-47c0-9258-aa7fe04c81fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.32,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e758fe4-cd4f-4430-83e9-53ba0c1da132",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.84
      },
      "kind": "disclaimer",
      "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ea95552-c490-49a4-9267-c5e0fa5f91e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.35,
        "y": 0.74
      },
      "kind": "legend",
      "text": "Each unique color indicates data from the same patient across both figures; PD (due to new lesions); Prior treatments include repotrectinib",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "472148d7-8dcc-4951-87e4-043f2e634b5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "list",
      "text": "Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fa0aa4b-bc0e-43e5-8249-10d3a58468b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ROS1 Resistance Mutations | NVL-520 Induced Rapid Responses in TKI-Resistant Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e000905a-5d23-4ce1-ba47-bb96e21ebe9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "72ae47d2-6e30-4886-abcc-72ad7bc60efd",
      "evidence": "table/data: Dose level and prior therapy history table",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 19,
      "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Preliminary efficacy and safety data are presented.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 19,
      "name": "Day In Life",
      "slug": "14-day-in-life",
      "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points",
      "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66",
      "evidence": "Preliminary efficacy data are presented.",
      "position": 1,
      "objective": "How do patients benefit from Nuvalent's therapies?",
      "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State",
      "confidence": 0.6,
      "description": "Humanize abstract data by walking through a single user's struggle and resolution"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}